ArticleBiopharmaceutics & drug disposition2026
Cyclooxygenase-2 Inhibition and Anti-Platelet Aggregation Activity of Astaxanthin-Hydrogel in Comparison to Celecoxib Against Rheumatoid Arthritis in Wistar Rat Model.
Article in Biopharmaceutics & drug disposition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis is an auto-immune disease, commonly treated with celecoxib (Cyclooxygenase-2 inhibitor), which comes with serious cardiovascular threats. Astaxanthin is a natural carotenoid, possessing extraordinary anti-inflammatory and anti-platelet aggregation qualities. The aim of this study was to investigate the superlative effects of astaxanthin-hydrogel to inhibiting the cyclooxygenase-2 in comparison to celecoxib and its cardiac side-effects, specifically platelet aggregation. Induction of rheumatoid arthritis was accomplished by type-II-collagen/Complete Freund's adjuvant followed by a booster dose of Incomplete Freund's adjuvant and confirmed by arthritic score calculation, CRP and ACCPA tests. Astaxanthin-hydrogel was subcutaneously injected into the neck and back of arthritic Wistar rats in comparison to oral-celecoxib. Cyclooxygenase-2 inhibitory activity was observed by rat ELISA kit and platelet aggregation was monitored by optical chrono-log aggregometer. Results were compared by statistical analysis, executed through IBMM SPSS. The anti-inflammatory activity of 20 mg/week astaxanthin-hydrogel to inhibiting the cyclooxygenase-2 for 6 weeks in arthritic wistar rats was found more effective in comparison to 20 mg/day celecoxib. Continued use of 40 mg/day celecoxib for 8 weeks has been seen involved with platelet aggregation, whereas the regimen consisting of 20 mg/week astaxanthin-hydrogel administered with 20 mg/d celecoxib for 8 weeks was observed with no platelet aggregation. Celecoxib monotherapy was found associated with a little risk of platelet aggregation, whereas along with astaxanthin-hydrogel, no platelet aggregation was found. Notably, astaxanthin-hydrogel was significant to suppress the cyclooxygenase-2 in comparison to celecoxib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.